Staphylococcus Aureus Protein A Immunoadsorption: The Rationale for Systemic Protein A Immunotherapy

REFERENCES

• Bansal SC, Bansal BR, Thomas HL, et al. Ex vivo removal of serum IgG in a patient with colon carcinoma: some biochemical, immunological and histological observations. Cancer. 1978;42:1–18.
   PubMed Web of Science ®Google Scholar
• Snyder HW Jr, Balint JP, Jones FR. Modulation of immunity and clinical responses in patients with cancer and autoimmune disease treated by extracorporeal immunoadsorption of plasma with protein A-silica (PROSORBA columns). Semin Hematol. 1989; 26:31–41.
   PubMedGoogle Scholar
• Terman DS, Young JB, Shearer WT. Preliminary observations of the effects on breast adenocarcinoma of plasma infused over immobilized protein A. N Engl J Med. 1981; 305:1159- 1200.
   Google Scholar
• Messerschmidt GL, Henry DH, Snyder HW Jr, et al. Protein A immunoadsorption in the treatment of malignant disease. J Clin Oncol. 1988; 6:203–212.
   PubMedGoogle Scholar
• Kinet, JP, Bensinger, WI, Balland, et al. Ex vivo perfusion of plasma over protein A columns in human mammary adenocarcinoma: role of Fc-binding capacity of protein A in the side effects and the tumoricidal response. Eur J Clin Invest. 1986; 16:50–55.
   PubMedGoogle Scholar
• Howe RB, Christie, DJ. Protein A immunoadsorption treatment in hematology: an overview. J Clin Apheresis. 1994; 9:31–32.
   PubMedGoogle Scholar
• Wiesenhutter CW, Irish BL, Bertram JH. Treatment of patients with refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: a pilot trail. J Rheumatol. 1994;21:804–812.
   Google Scholar
• Snyder HW, Cochran SK, Balint JP Jr, et al. Experience with Protein A-Immunoadsorption in treatment- resistant adult immune thrombocytopenic purpura. Blood. 1992; 79:2237–2245.
   PubMed Web of Science ®Google Scholar
• Sinclair NR StC. Antibody-antigen complexes: biological consequences. In: Encyclopedia of Human Biology, Vol 1. New York: Academic; 1991:297–305.
   Google Scholar
• Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J. 1991; 5:2684–2690.
   PubMed Web of Science ®Google Scholar
• Sandor M, Lynch RG. The biology and pathology of Fc receptors. J Clin Immunol. 1993; 4:237–246.
   Google Scholar
• Ravetch JV. Fc receptors: Rubor redux. Cell. 1994; 78:553–560.
   PubMed Web of Science ®Google Scholar
• Wallace PK, Howell AL, Fanger MW. Role of Fc receptors in cancer and infectious disease. J Leukocyte Biol. 1994; 55:816–826.
   PubMed Web of Science ®Google Scholar
• Cowan FM. A method of treating cellular Fc receptor mediated immune disorders. U.S. Patent Number: 5,189,014, 23 February 1993 (original application Serial No. 99, 741 filed 3 December 1979).
   Google Scholar
• Cowan FM, Madsen JM. The role of immunoglobulin binding factors in the pathogenesis and therapy of AIDS. Med Hypothesis. 1994;43:172–176.
   PubMedGoogle Scholar
• Cambier JC. Antigen and Fc receptor signaling: the awesome power of the immunoreceptor tryosine- based activation motif (ITAM). J Immunol. 1995; 155:3281 -3285.
   PubMed Web of Science ®Google Scholar
• Chamow SM, Ashkenazi A. Immunoadhesesins: principles and applications. TIBTECH 1996; 14:52- 60.
   Google Scholar
• Ray PK, Raychaudhari S, Allen P. Mechanisms of regression of mammary adenocarcinoma in rats following plasma adsorption over Protein A containing Staphyloco ccus aureus. Cancer Res. 1982; 42:4970.
   PubMed Web of Science ®Google Scholar
• Cowan FM, Klein DL, Armstrong GR, Pearson JW, Ablashi DV, Bensinger WI. Inhibition of rat adenocarcinoma metastases by Staphylococcus aureus protein A. Pharmacotherapy. 1982; 36:29–31.
   Google Scholar
• Engelman RW, Good RA, Day NK. Clearance of retroviremia and regression of malignancy in cats with leukemia-lymphoma during treatment with Staphylococcal protein A. Cancer Detect Prev. 1987; 10:435–444.
   PubMedGoogle Scholar
• Das C, Langone JL. Dissociation between murine spleen cell mitogenic activity of enterotoxin contaminants and anti-tumor activity of staphylococcal protein A. J Immunol. 1989; 142:2943–2948.
   PubMedGoogle Scholar
• Singh KP, Shau H, Gupta RK, Kopald K, Ray PK. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes. Immunopharmacol Immunotoxicol. 1992; 14:79- 103.
   Google Scholar
• Hjelm H, Sjodahl J, Sjoquist J. Immunologically active and structurally similar fragments of protein A from Staphyloco ccus aureus. Eur J Biochem. 1975; 57:395–403.
   PubMedGoogle Scholar
• Cowan FM, Klein DL, Armstrong GR, Stylos WA, Pearson JW. Suppression of DNA synthesis in mitogen stimulated leukocytes with partial trypsin digests of Staphyloco ccus aureus protein A. Biomedi- cine. 1979; 31:220–222.
   PubMedGoogle Scholar
• Lopez DA, Williams RM, Miehlke K. Enzymes: The Fountain of Life. Charleston, SC: Neville; 1994.
   Google Scholar
• Godfrey MAJ, Kwasowski P, Clift R, Marks V. A sensitive enzyme-linked immunosorbent assay (ELISA) for the detection of staphylococ cal protein A c(SpA) present as a trace contaminant of murine immunoglobulins purified on immobilized protein A. J Immunol Methods. 1992; 149:21–27.
   PubMed Web of Science ®Google Scholar
• Friberger P. Chromogenic peptide substrates. Scand J Clin Invest. 1991; 42:1–98.
   Google Scholar
• Twining SS. Fluorecein isothiocyanate-labeled casein assay for proteolytic enzymes. Anal Biochem. 1984; 143:30–34.
   PubMed Web of Science ®Google Scholar
• Forgren A, Sjoquest J. Protein A from Staphylococcus aureus, IV: production of anaphylaxis-like cutaneous and systemic reactions in nonimmunized guinea pigs. J Immunol. 1967; 100:530–534.
   Google Scholar
• Cowan FM, Shih T-M, Lenz DE, Madsen JM, Broomfield CA. A hypothesis for synergistic toxicity of organophosphorus poisoning-induced cholnergic crisis and anaphylactoid reactions. J Appl Toxicol. 1996; 16:25–33.
   PubMed Web of Science ®Google Scholar
• Smith RE, Gottschall JL, Pisciotta AV. Life-threatening reactions to staphylococcal protein A immuno- modulation. J Clin Apheresis. 1992;7:4–5.
   PubMedGoogle Scholar
• Arbiser JL, Dzieczkowski JS, Harmon JV, Duncan LM. Leukocytoclastic vasculitis following Staphylococcal protein A column immunoadsorption therapy. Arch Dermatol. 1995; 131:707–709.
   PubMedGoogle Scholar
• Debre M, Bonnet M-C, Fridman W-H, et al. Infusion of Fc fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993; 342:945–949.
   PubMed Web of Science ®Google Scholar
• Iganas M. Comparison of mechanisms of interaction between protein A from Staphyloco ccus aureus and human monoclonal IgG, IgA, and IgM in relationship to the classical Fc and alterative F(ab')2 protein A interaction. Scand J Immunol. 1981; 13:343.
   PubMedGoogle Scholar
• Sasso EH, Silverman GJ, Mannik M. Human IgA and IgG F(ab')2 that bind to Staphyloco ccus protein A belong to the VHIII subgroup. J Immunol. 1991; 147:1877-1883.
   PubMedGoogle Scholar
• Berverian L, Goodglick L, Kipps TJ, Braun. Immunoglobulin VH3 gene products: natural ligands for HIV gp 120. Science. 1993; 261:1588-1591.
   Google Scholar
• Silverman GJ. Human antibody responses to bacterial antigens: studies of a model conventional antigen and a proposed model B cell superantigen. Int Rev Immunol. 1992; 9:57–78.
   PubMedGoogle Scholar
• Ashman RF, Peckham D, Stunz LL. Fc receptor off-signal in B cell involves apoptosis. J Immunol. 1996; 157:5-11.
   PubMedGoogle Scholar
• Sinclair NR StC, Panoskaltsis A. Immunoregulation and Fc signals. Immunol Today. 1987; 8:76–79.
   Google Scholar
• Romagnani SMG, et al. Demonstration on protein A of two distinct immunoglobulin-binding sites and their role in the mitigenic activity of Staphylococcus aureus Cowan I on human B cells. J Immunol. 1982; 129:596.
   PubMedGoogle Scholar
• Zaidi SIA, Raisuddin S, Jafri A, Singh KP, Ray PK. Modulation of anti-sheep erythrocyte primary antibody response by protein A in normal mice. Immunopharmacol Immunotoxicol. 1994; 16:85–96.
   PubMed Web of Science ®Google Scholar